Ignite Creation Date:
2024-05-06 @ 8:13 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06299163
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-02-26
Brief Title:
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Sponsor:
Numab Therapeutics AG
Organization:
Numab Therapeutics AG
Study Overview
Official Title:
A Phase 1 Study of NM32-2668 Anti-ROR1CD3Anti-HSA Tri-Specific Antibody in Adult Patients With Selected Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human open-label multi-center Phase 1 dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity to determine the maximal tolerated dose and recommended Phase 2 dose define the pharmacokinetics to explore the pharmacodynamics and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None